USE OF TOCILIZUMAB IN COVID-19 INFECTION
Author(s): Pranjal Toshniwal and Shiv Joshi*
Background: Cytokine storm is one of the severe clinical outcome of COVID-19 which is indicate the patient’s critical condition. The progression of cytokine storm is extremely fast and needs to be control any how in order to prevent the patients from meeting with fatal clinical outcome.
Summary: The novel Coronavirus created so much havoc because of two reasons. First the high transmissibility of the novel Coronavirus makes it extremely difficult to contain in certain geographical extent. Second is its capacity to create unmanageable medical complications which can give rise to fatality figures. Repurposing of drugs to treat the patients of COVID-19 was inevitable as no course of treatment or medications were viable. Till date no definite treatment is available for COVID-19 and ad hoc administration of drugs according to the condition of patient and its clinical history is being done. The efficacy of the tocilizumab has been an issue of discussion all over the world as various studies has indicated different suggestion regarding the administration of drugs.
Conclusion: Efficacy of the tocilizumab has been tested for quite some time and international cohort is needed to authenticate the results coming from the different pockets of the world. The patients obtaining fatal clinical outcome post administration of tocilizumab must be examined for the necessary reason. This can create a negative list for the health care professional among which administration of tocilizumab is prohibited. The efficacy in many patients must also be studied in detail to list all the positive outcome of the administration of drugs.